These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 1782306)

  • 1. Famotidine (20 mg) b.d. relieves gastrooesophageal reflux symptoms in patients without erosive oesophagitis. Famotidine/GERD Investigation Group.
    Robinsen M; Decktor DL; Stone RC; Pevelery M; Barden P; Moyer R; Holt S; Root J; Hufnagel K; Humphries TJ
    Aliment Pharmacol Ther; 1991 Dec; 5(6):631-43. PubMed ID: 1782306
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Symptomatic therapy with famotidine in non-erosive gastro-esophageal reflux. Results of an open multicenter study].
    Heckers H; Lübbecke F
    Arzneimittelforschung; 1995 Apr; 45(4):499-504. PubMed ID: 7779150
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized, placebo-controlled comparison of famotidine 20 mg b.d. or 40 mg b.d. in patients with erosive oesophagitis.
    Simon TJ; Berenson MM; Berlin RG; Snapinn S; Cagliola A
    Aliment Pharmacol Ther; 1994 Feb; 8(1):71-9. PubMed ID: 8186349
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dose--response effect of famotidine on patterns of gastro-oesophageal reflux.
    Orr WC; Robinson MG; Humphries TJ; Antonello J; Cagliola A
    Aliment Pharmacol Ther; 1988 Jun; 2(3):229-35. PubMed ID: 2979247
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Famotidine in the management of gastro-oesophageal reflux.
    Okoth FA; Lule GN; Ogutu EO; Pilczer S; Dubois C
    East Afr Med J; 1994 Jan; 71(1):44-8. PubMed ID: 8055765
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of famotidine on oesophageal sensitivity in gastro-oesophageal reflux disease.
    Marrero JM; de Caestecker JS; Maxwell JD
    Gut; 1994 Apr; 35(4):447-50. PubMed ID: 8174979
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Omeprazole is more effective than cimetidine for the relief of all grades of gastro-oesophageal reflux disease-associated heartburn, irrespective of the presence or absence of endoscopic oesophagitis.
    Bate CM; Green JR; Axon AT; Murray FE; Tildesley G; Emmas CE; Taylor MD
    Aliment Pharmacol Ther; 1997 Aug; 11(4):755-63. PubMed ID: 9305486
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized, double-blind, placebo-controlled clinical study of the histamine H2-receptor antagonist famotidine in Japanese patients with nonerosive reflux disease.
    Hongo M; Kinoshita Y; Haruma K
    J Gastroenterol; 2008; 43(6):448-56. PubMed ID: 18600389
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Famotidine relieves symptoms of gastroesophageal reflux disease and heals erosions and ulcerations. Results of a multicenter, placebo-controlled, dose-ranging study. USA Merck Gastroesophageal Reflux Disease Study Group.
    Sabesin SM; Berlin RG; Humphries TJ; Bradstreet DC; Walton-Bowen KL; Zaidi S
    Arch Intern Med; 1991 Dec; 151(12):2394-400. PubMed ID: 1746996
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Famotidine vs. omeprazole: a prospective randomized multicentre trial to determine efficacy in non-erosive gastro-oesophageal reflux disease.
    Fujiwara Y; Higuchi K; Nebiki H; Chono S; Uno H; Kitada K; Satoh H; Nakagawa K; Kobayashi K; Tominaga K; Watanabe T; Oshitani N; Arakawa T
    Aliment Pharmacol Ther; 2005 Jun; 21 Suppl 2():10-8. PubMed ID: 15943841
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of famotidine and omeprazole in healing symptoms of non-erosive gastro-oesophageal reflux disease: randomized-controlled study of gastro-oesophageal reflux disease.
    Wada T; Sasaki M; Kataoka H; Tanida S; Itoh K; Ogasawara N; Oshima T; Togawa S; Kubota E; Yamada T; Mori Y; Fujita F; Ohara H; Nakao H; Sobue S; Joh T; Itoh M
    Aliment Pharmacol Ther; 2005 Jun; 21 Suppl 2():2-9. PubMed ID: 15943840
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acid suppression by famotidine 20 mg twice daily or 40 mg twice daily in preventing relapse of endoscopic recurrence of erosive esophagitis.
    Simon TJ; Roberts WG; Berlin RG; Hayden LJ; Berman RS; Reagan JE
    Clin Ther; 1995; 17(6):1147-56. PubMed ID: 8750406
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The efficacy of hydrotalcite compared with OTC famotidine in the on-demand treatment of gastroesophageal reflux disease: a non-inferiority trial.
    Konturek JW; Beneke M; Koppermann R; Petersen-Braun M; Weingärtner U
    Med Sci Monit; 2007 Jan; 13(1):CR44-9. PubMed ID: 17179910
    [TBL] [Abstract][Full Text] [Related]  

  • 14. On-demand treatment of acute heartburn with the antacid hydrotalcite compared with famotidine and placebo: randomized double-blind cross-over study.
    Holtmeier W; Holtmann G; Caspary WF; Weingärtner U
    J Clin Gastroenterol; 2007 Jul; 41(6):564-70. PubMed ID: 17577112
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Famotidine in gastroesophageal reflux disease (GERD).
    Wesdorp IC
    Hepatogastroenterology; 1992 Feb; 39 Suppl 1():24-6. PubMed ID: 1577391
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized clinical trial: a double-blind, placebo-controlled study to assess the clinical efficacy and safety of alginate-antacid (Gaviscon Double Action) chewable tablets in patients with gastro-oesophageal reflux disease.
    Wilkinson J; Wade A; Thomas SJ; Jenner B; Hodgkinson V; Coyle C
    Eur J Gastroenterol Hepatol; 2019 Jan; 31(1):86-93. PubMed ID: 30272584
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of rabeprazole on heartburn symptom resolution in patients with non-erosive and erosive gastro-oesophageal reflux disease: a multicenter study from Japan.
    Miwa H; Sasaki M; Furuta T; Koike T; Habu Y; Ito M; Fujiwara Y; Wada T; Nagahara A; Hongo M; Chiba T; Kinoshita Y;
    Aliment Pharmacol Ther; 2007 Jul; 26(1):69-77. PubMed ID: 17555423
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nizatidine versus placebo in gastro-oesophageal reflux disease: a 6-week, multicentre, randomised, double-blind comparison. Nizatidine Gastroesophageal Reflux Disease Study Group.
    Cloud ML; Offen WW
    Br J Clin Pract Suppl; 1994 Nov; 76():11-9. PubMed ID: 7794700
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cisapride 20 mg b.i.d. provides symptomatic relief of heartburn and related symptoms of chronic mild to moderate gastroesophageal reflux disease. CIS-USA-52 Investigator Group.
    Castell DO; Sigmund C; Patterson D; Lambert R; Hasner D; Clyde C; Zeldis JB
    Am J Gastroenterol; 1998 Apr; 93(4):547-52. PubMed ID: 9576446
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Distinguishing the impact of dexlansoprazole on heartburn vs. regurgitation in patients with gastro-oesophageal reflux disease.
    Peura DA; Pilmer B; Hunt B; Mody R; Perez MC
    Aliment Pharmacol Ther; 2013 Nov; 38(10):1303-11. PubMed ID: 24118079
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.